The table below indicates the characteristics of patients included in the FOXFIRE Combined Analysis. There were no significant differences in baseline patient characteristics. A majority of patients had poor prognostic factors at baseline: almost 90% of patients had synchronous disease, more than half of the patients had primary tumor in situ and more than a third of the patients had extra-hepatic metastases.

*Biologic agents: Bevacizumab in SIRFLOX and FOXFIRE Global. Bevacizumab or cetuximab in FOXFIRE. Biologicals allowed at investigator’s discretion, per institutional practice.

Wasan HS et al. Lancet Oncol 2017; 18: 1159-71.

Now leaving

You are about to leave the Sirtex Web site. This link is provided to you as a service and will take you to a site maintained by a third party who is solely responsible for the content.

Please be aware that Sirtex takes no responsibility for content of these external sites, nor do we endorse, warrant or guarantee the products, services or information described or offered on other internet sites.

Click 'Continue' to proceed to the third-party Web site.



You are now leaving your current region

The Sirtex site you are linking to is intended only for healthcare practitioners and patients outside your current region. Any products discussed herein may have different approved product labeling; therefore, any information provided may not be appropriate for use in your region.

Click 'Continue' to proceed to the other Sirtex region Web site.